De Novo Lipogenesis (ACC/FASN/SCD1): Regulation and Validation
Three Steps, Three Different Products
| Enzyme | Reaction | Product | Note |
|---|---|---|---|
| ACC1 (ACACA) | Acetyl-CoA → malonyl-CoA, cytosolic | Malonyl-CoA for FASN | Also the precursor of the CPT1A inhibitor pool |
| ACC2 (ACACB) | Acetyl-CoA → malonyl-CoA, mitochondrial-associated | Malonyl-CoA that inhibits CPT1A | Loss increases fatty acid oxidation |
| FASN | Malonyl-CoA + acetyl-CoA → palmitate | C16:0 saturated fatty acid | The committed step of synthesis |
| SCD1 | C16:0 and C18:0 → C16:1 and C18:1 | Monounsaturated fatty acids | Determines membrane and esterification substrate saturation |
| ELOVL6 | C16 → C18 elongation | Stearate and longer | Often co-regulated with SCD1 |
Important distinction. ACC1 and ACC2 are products of different genes with different subcellular localisation and different functions. ACC1 supplies malonyl-CoA to FASN; ACC2 supplies the malonyl-CoA pool that gates CPT1A. An ACC2 knockout increases fatty acid oxidation. A study that knocks down "ACC" without specifying the isoform has not defined what it perturbed, and the expected direction depends entirely on which one was lost.
Caveat on SCD1. SCD1 does not change the amount of fatty acid synthesised; it changes the saturation of the product. Loss of SCD1 reduces monounsaturated species and raises saturated species at the same total synthesis. In several models this increases ER stress and lipotoxicity while reducing total lipid, which is the clearest example in this cluster of "less lipid, worse outcome".
Part 1 — Measuring Synthesis Rate
| Method | What it measures | Assumption | Limitation |
|---|---|---|---|
| ¹³C-acetate incorporation into fatty acids | Fraction of newly made fatty acid from acetate | Acetate reaches the cytosolic acetyl-CoA pool | Acetate is also oxidised; compartment mixing |
| ¹³C-glucose incorporation | Contribution of glucose carbon to synthesis | Glucose is the main carbon source | Underestimates when glutamine contributes |
| Deuterated water (D₂O) incorporation | Total synthesis rate, independent of carbon source | Body water equilibrates with the precursor pool | Requires careful background correction |
| ¹⁴C-acetate incorporation | Synthesis rate | Same as ¹³C | Radioactive; same compartment issues |
| Enzyme expression or activity | Capacity | — | Not a rate |
| Fatty acid speciation | Product composition | — | Not a rate |
Readout note on D₂O. Deuterium incorporation measures the number of C–H bonds formed during synthesis and is therefore closer to a true synthesis rate than tracer incorporation from a single carbon source, because it does not depend on which substrate supplied the carbon. It requires accurate measurement of the precursor enrichment and a background correction from a non-synthesising control; done properly, it is the strongest of these methods.
The weakest, and the most common, is enzyme expression. FASN and ACC1 are transcriptionally regulated by SREBP1c and by carbohydrate response elements, so expression tracks the nutritional state; it does not track flux when substrate supply changes independently.
Part 2 — What Each Perturbation Actually Does
| Perturbation | Expected synthesis | Expected saturation | Expected toxicity |
|---|---|---|---|
| ACC1 knockdown | Down | Unchanged or down | Often down, if synthesis was driving storage overload |
| ACC2 knockout | Unchanged | Unchanged | Often down, because oxidation rises |
| FASN knockdown | Down | Down | Variable; depends on whether membrane synthesis is limiting |
| SCD1 knockout | Unchanged | Saturated species up | Often up, through ER stress and membrane rigidification |
| SCD1 overexpression | Unchanged | Monounsaturated up | Often down, in saturated-fatty-acid models |
| Acetyl-CoA supply reduced (ACLY knockdown) | Down | Down | Down, but confounded by reduced histone acetylation |
The fourth and fifth rows are the clinically relevant ones: SCD1 is a widely pursued target, and its loss produces the opposite of the intended effect in several lipotoxicity models. Any SCD1 programme needs to measure ER stress and species saturation, not only total lipid.
Caveat on ACLY. ACLY supplies cytosolic acetyl-CoA for both lipogenesis and histone acetylation. A knockdown reduces both, and the resulting phenotype cannot be attributed to lipid synthesis without a rescue that restores the acetyl-CoA pool independently.
Part 3 — Regulation: Two Transcriptional Arms
| Arm | Activator | Targets | Timescale |
|---|---|---|---|
| SREBP1c | Insulin, LXR, carbohydrate | ACC1, FASN, SCD1, ELOVL6 | Hours |
| ChREBP | Glucose (via xylulose-5-phosphate) | ACC1, FASN, ChREBPβ | Hours |
| Post-translational | AMPK phosphorylates ACC1/ACC2 | Acute inhibition of ACC activity | Minutes |
| Allosteric | Citrate activates ACC; palmitoyl-CoA inhibits | Acute | Minutes |
Important distinction. Transcriptional and post-translational regulation act on different timescales and are measured differently. A 30-minute change in malonyl-CoA is a phosphorylation event; a 24-hour change in FASN protein is a transcriptional one. An experiment that measures protein at 24 hours and infers flux at 1 hour has crossed the two.
Readout note on AMPK. ACC phosphorylation at S79 is the standard readout of AMPK activity toward ACC, and it reports the acute arm. It does not report flux, because ACC activity also depends on substrate and on allosteric regulators, and because phosphorylation is reversible within minutes.
Part 4 — Validation Design
| Step | Measurement | Question answered |
|---|---|---|
| 1 | Synthesis rate (D₂O or tracer) at baseline | How much synthesis occurs |
| 2 | Fatty acid speciation | What is being made |
| 3 | Triglyceride and phospholipid species | Where the product went |
| 4 | ER stress and viability | Whether the change is tolerated |
| 5 | Rescue with the missing product (oleate for SCD1; palmitate for FASN) | Which product mattered |
| 6 | Substrate supply control (acetate, glucose, glutamine) | Whether the change was supply-driven |
The fifth step is decisive for SCD1 and is often omitted. If oleate restores viability in an SCD1 knockout, the lesion is desaturation; if it does not, the phenotype is downstream or unrelated to the lipid.
Part 5 — Model Requirements
| Requirement | Why |
|---|---|
| Medium glucose and insulin documented | Both drive SREBP1c and ChREBP |
| Serum lot and lipid content | Lipoprotein lipids suppress synthesis |
| Oxygen tension | Synthesis consumes NADPH and acetyl-CoA; hypoxia shifts the balance |
| Fatty acid supplementation recorded | Exogenous fatty acids suppress de novo synthesis |
| Proliferation measured | Membrane synthesis demand drives lipogenesis in dividing cells |
| Isotope precursor enrichment measured | Otherwise incorporation is uninterpretable |
The fourth row is a common confound: cells cultured in medium with added palmitate or serum lipids downregulate de novo synthesis, so a "low lipogenesis" phenotype may reflect the medium rather than the genotype.
Part 6 — Failures That Recur
- • "ACC" without isoform specification, so the expected direction is undefined.
- • Expression reported as synthesis rate.
- • SCD1 loss interpreted as reduced lipogenesis, when the amount is unchanged and the composition shifted.
- • Rescue with oleate omitted, leaving the mechanism untested.
- • Acetate tracer used without measuring precursor enrichment, or in cells that oxidise acetate heavily.
- • Serum lipids and exogenous fatty acids unrecorded.
- • ACLY knockdown attributed to lipogenesis, when histone acetylation also fell.
- • AMPK phosphorylation reported as ACC flux.
Part 7 — Where This Article Connects
This is the synthesis article of the lipid cluster: it feeds the esterification and storage modules described in the pillar, and it gates oxidation through the malonyl-CoA pool described in the fatty acid oxidation article. The SCD1 phenotype article covers the interpretive problem in detail; the triglyceride assay article covers the product measurement.
If you need lipogenesis measured as a rate with isotope enrichment controls, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Synthesis rate, isoform expression and the partition between saturated and monounsaturated products vary with cell type, medium, insulin and proliferation. The expected directions above are conditional.
Enzyme expression does not establish synthesis rate, and a change in total lipid does not establish a change in synthesis.
Scientific interpretation and experimental design
- • ACC1 and ACC2 are different experiments. Specify the isoform.
- • SCD1 changes composition, not amount.
- • Synthesis rate needs a tracer with enrichment data. Expression is not a rate.
- • Acetate is oxidised. Compartment mixing limits its interpretation.
- • Medium lipids suppress synthesis. Record them.
- • Rescue with the missing product identifies the mechanism.
- • Transcriptional and acute regulation are different timescales.
Selected references for further reading
- • Abu-Elheiga L, et al. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science. 2001;291:2613–2616.
- • Flowers MT, Ntambi JM. Stearoyl-CoA desaturase and its relation to high-carbohydrate diets and obesity. Biochimica et Biophysica Acta. 2009;1791:85–91.
- • Hellerstein MK, Neese RA. Mass isotopomer distribution analysis at eight years: theoretical, analytic, and experimental considerations. American Journal of Physiology. 1999;276:E1146–E1170.
- • Softic S, et al. Dietary sugars alter hepatic fatty acid oxidation in mice via effects on malonyl-CoA and CPT1A. JCI Insight. 2019;4:e128760.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »